NO20090596L - Antivirale fosfinatforbindelser - Google Patents

Antivirale fosfinatforbindelser

Info

Publication number
NO20090596L
NO20090596L NO20090596A NO20090596A NO20090596L NO 20090596 L NO20090596 L NO 20090596L NO 20090596 A NO20090596 A NO 20090596A NO 20090596 A NO20090596 A NO 20090596A NO 20090596 L NO20090596 L NO 20090596L
Authority
NO
Norway
Prior art keywords
compounds
phosphinate compounds
antiviral
antiviral phosphinate
methods
Prior art date
Application number
NO20090596A
Other languages
English (en)
Norwegian (no)
Inventor
Aesop Cho
Choung U Kim
Maria Fardis
Jianying Wang
Anthony Casarez
Kleem Chaudhary
Michael Clarke
Edward Doerffler
Hyungjung Pyun
Xiaoning C Sheng
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of NO20090596L publication Critical patent/NO20090596L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20090596A 2006-07-07 2009-02-06 Antivirale fosfinatforbindelser NO20090596L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81948806P 2006-07-07 2006-07-07
US83290806P 2006-07-24 2006-07-24
PCT/US2007/015664 WO2008005565A2 (en) 2006-07-07 2007-07-06 Antiviral phosphinate compounds

Publications (1)

Publication Number Publication Date
NO20090596L true NO20090596L (no) 2009-04-01

Family

ID=38626760

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090596A NO20090596L (no) 2006-07-07 2009-02-06 Antivirale fosfinatforbindelser

Country Status (19)

Country Link
US (4) US7893264B2 (de)
EP (2) EP2043658B1 (de)
JP (3) JP2009542698A (de)
KR (1) KR20090026216A (de)
CN (1) CN102532198A (de)
AR (1) AR061840A1 (de)
AT (1) ATE554776T1 (de)
AU (1) AU2007269567B2 (de)
BR (1) BRPI0713961A2 (de)
CA (1) CA2656356C (de)
EA (1) EA018098B1 (de)
ES (2) ES2531315T3 (de)
HR (1) HRP20090076A2 (de)
IL (1) IL195489A0 (de)
MX (1) MX2009000236A (de)
NO (1) NO20090596L (de)
TW (1) TW200819460A (de)
WO (1) WO2008005565A2 (de)
ZA (1) ZA200810400B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. C형 간염 바이러스 복제의 신규 억제제
JP2009542698A (ja) * 2006-07-07 2009-12-03 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルスホスフィナート化合物
EA201071034A1 (ru) * 2008-04-15 2011-06-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликаций вируса гепатита с
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス,インコーポレイテッド ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤
AR077125A1 (es) * 2009-06-23 2011-08-03 Gilead Sciences Inc Combinaciones farmaceuticas utiles para tratar el vhc
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
WO2011156757A1 (en) * 2010-06-10 2011-12-15 Gilead Sciences, Inc. Combination of anti-hcv compounds with ribavirin for the treatment of hcv
US20130273005A1 (en) * 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2709613B2 (de) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Verfahren zur behandlung von hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
EP2583677A3 (de) 2011-10-21 2013-07-03 Abbvie Inc. Verfahren zur Behandlung von HCV mit wenigstens zwei direkt angreifenden viralen Mitteln, Ribavirin aber nicht Interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (de) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Inhibitoren des hepatitis-c-virus
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2950786B1 (de) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Kombinationsformulierung zweier antiviraler verbindungen
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C型肝炎ウイルス阻害剤
CN103539833B (zh) * 2013-09-29 2016-02-03 北京林业大学 高活性α-葡萄糖苷酶抑制肽及其制备方法和用途
CN103539831B (zh) * 2013-09-29 2016-02-03 北京林业大学 山杏α-葡萄糖苷酶抑制肽及其制备方法和用途
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0533833B1 (de) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorylierte prodrugs
EP0481214B1 (de) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Wirkstoffvorläufer von Phosphonaten
DE4308096A1 (de) 1993-03-13 1994-09-15 Hoechst Ag Prodrug-Derivate von Enzyminhibitoren mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
EP0719273B1 (de) 1993-09-17 2010-11-03 Gilead Sciences, Inc. Nukleotidanaloge
JPH07183249A (ja) 1993-12-22 1995-07-21 Nec Yamagata Ltd イオン注入工程管理方法
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5968788A (en) * 1995-08-28 1999-10-19 Toray Industries, Inc. Method for producing folic acid
US6004977A (en) 1996-12-27 1999-12-21 Hoechst Marion Roussel, Inc. N-(pyridinylamino) isoindolines and related compounds
DE19843360A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
JP4733023B2 (ja) * 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー C型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
RS51974B (sr) * 2004-07-16 2012-02-29 Gilead Sciences Inc. Antivirusna jedinjenja
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
JP5154406B2 (ja) * 2005-04-13 2013-02-27 アステックス、セラピューティックス、リミテッド 医薬化合物
MX2008001166A (es) 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007014922A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2009542698A (ja) 2006-07-07 2009-12-03 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルスホスフィナート化合物
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
AR077125A1 (es) 2009-06-23 2011-08-03 Gilead Sciences Inc Combinaciones farmaceuticas utiles para tratar el vhc
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
CA2656356C (en) 2013-04-09
WO2008005565A9 (en) 2009-01-29
ATE554776T1 (de) 2012-05-15
HRP20090076A2 (hr) 2009-05-31
WO2008005565A3 (en) 2008-05-02
JP2015083605A (ja) 2015-04-30
EA200900154A1 (ru) 2009-06-30
EP2043658B1 (de) 2012-04-25
JP2009542698A (ja) 2009-12-03
US7893264B2 (en) 2011-02-22
ES2531315T3 (es) 2015-03-12
JP6010640B2 (ja) 2016-10-19
BRPI0713961A2 (pt) 2012-11-27
ZA200810400B (en) 2011-12-28
US8586744B2 (en) 2013-11-19
WO2008005565A2 (en) 2008-01-10
KR20090026216A (ko) 2009-03-11
US20110081314A1 (en) 2011-04-07
EP2422791B1 (de) 2014-12-17
US20090227491A1 (en) 2009-09-10
AU2007269567A1 (en) 2008-01-10
MX2009000236A (es) 2009-01-23
CN102532198A (zh) 2012-07-04
EA018098B1 (ru) 2013-05-30
US8674088B2 (en) 2014-03-18
US20080057031A1 (en) 2008-03-06
TW200819460A (en) 2008-05-01
JP2012107061A (ja) 2012-06-07
IL195489A0 (en) 2009-09-01
EP2422791A1 (de) 2012-02-29
EP2043658A2 (de) 2009-04-08
ES2388969T3 (es) 2012-10-22
HK1127295A1 (en) 2009-09-25
AU2007269567B2 (en) 2012-11-08
CA2656356A1 (en) 2008-01-10
US20110082112A1 (en) 2011-04-07
AR061840A1 (es) 2008-09-24

Similar Documents

Publication Publication Date Title
NO20090596L (no) Antivirale fosfinatforbindelser
NO20071078L (no) Antivirale forbindelser
NO20070866L (no) Antivirale forbindelser.
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
MY153915A (en) Organic compounds
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
DK2089369T3 (da) 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
TW200806280A (en) Pharmaceutical compositions
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
EA200970156A1 (ru) Пиридизиноновые производные
TW201713640A (en) Bruton's tyrosine kinase inhibitors
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
TN2009000291A1 (en) Inhibitors of mek
NO20090783L (no) Pyrimidonforbindelser som inhibitorer av GSK-3
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
UA94749C2 (en) Benzimidazole modulators of vr1
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
MX2009010174A (es) Derivados de aza-adamantano ester y carbamato y metodos de uso de los mismos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application